- Home
- MRC vs AUPH Comparison
MRC vs AUPH Comparison
Compare MRC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRC
- AUPH
- Stock Information
- Founded
- MRC 1921
- AUPH 1993
- Country
- MRC United States
- AUPH Canada
- Employees
- MRC N/A
- AUPH N/A
- Industry
- MRC Industrial Machinery/Components
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- MRC Industrials
- AUPH Health Care
- Exchange
- MRC Nasdaq
- AUPH Nasdaq
- Market Cap
- MRC 1.1B
- AUPH 999.8M
- IPO Year
- MRC 2012
- AUPH 1999
- Fundamental
- Price
- MRC $12.41
- AUPH $7.90
- Analyst Decision
- MRC Strong Buy
- AUPH Strong Buy
- Analyst Count
- MRC 3
- AUPH 2
- Target Price
- MRC $15.00
- AUPH $11.50
- AVG Volume (30 Days)
- MRC 712.6K
- AUPH 1.4M
- Earning Date
- MRC 05-06-2025
- AUPH 05-12-2025
- Dividend Yield
- MRC N/A
- AUPH N/A
- EPS Growth
- MRC N/A
- AUPH N/A
- EPS
- MRC N/A
- AUPH 0.27
- Revenue
- MRC $2,946,000,000.00
- AUPH $247,295,000.00
- Revenue This Year
- MRC $4.95
- AUPH $12.15
- Revenue Next Year
- MRC $6.71
- AUPH $18.31
- P/E Ratio
- MRC $24.63
- AUPH $29.47
- Revenue Growth
- MRC N/A
- AUPH 29.20
- 52 Week Low
- MRC $9.23
- AUPH $5.15
- 52 Week High
- MRC $15.41
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- MRC 53.58
- AUPH 42.36
- Support Level
- MRC $12.04
- AUPH $7.96
- Resistance Level
- MRC $12.74
- AUPH $8.58
- Average True Range (ATR)
- MRC 0.27
- AUPH 0.32
- MACD
- MRC -0.06
- AUPH -0.03
- Stochastic Oscillator
- MRC 28.46
- AUPH 31.22
About MRC MRC Global Inc.
MRC Global Inc distributes pipes, valves, fittings, and other infrastructure products and services to diversified gas utility, energy, and industrial end-markets. It provides supply chain solutions, technical product service and a digital platform for customers globally. It offers a range of PVF, oilfield supply, valve automation and modification, measurement, instrumentation, and other general and specialty products. Its geographical segments include the United States and International. It generates the majority of its revenue from the United States.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.